Policy Developments - The National Healthcare Security Administration (NHSA) announced that by the end of 2025, all coordinated areas in the country must implement instant settlement for medical insurance funds [2] - By the end of 2026, instant settlement funds should account for over 80% of the local medical insurance fund's monthly settlement funds, covering various medical expenses [2] Industry Developments - Jiangxi Province is promoting the development of modern seed industry for traditional Chinese medicine, focusing on the protection of medicinal material resources and the establishment of breeding bases [3] - The company Jiuzhoutong received approval for the market launch of the chemical raw material drug, Glycopyrrolate, which will enhance its product line and market competitiveness [5] - Sichuan Shuangma's subsidiary obtained approval for the chemical raw material drug, Leuprolide Acetate, further strengthening its competitive advantage in the domestic raw material drug sector [6] Financial Reports - Guobang Pharmaceutical reported a 23.17% year-on-year increase in net profit for Q3, despite a 5.39% decline in revenue [8] Investment Activities - OxTium Technology completed several million yuan in angel+ round financing, led by Sequoia China Seed Fund [11] Clinical Research - Eli Lilly announced positive results from two Phase 3 clinical trials for orforglipron, showing significant improvements in blood sugar control and weight loss for type 2 diabetes patients [14] Shareholder Actions - Kangtai Medical announced that major shareholder Wang Guili reduced her holdings by 4.24 million shares, decreasing her ownership to 8.95% [17]

Core Viewpoint - The company Kyushu Tong (600998.SH) announced that its subsidiary Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd. received approval from the National Medical Products Administration for the marketing application of Glycopyrrolate, a quaternary ammonium anticholinergic drug [1] Group 1: Product Approval - The approval notification for Glycopyrrolate was issued on October 16, 2025 [1] - Glycopyrrolate is indicated for conditions such as gastric and duodenal ulcers, chronic gastritis, and for maintenance treatment in adults with chronic obstructive pulmonary disease (COPD) [1] Group 2: Drug Mechanism and Applications - Glycopyrrolate selectively acts on the gastrointestinal tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] - The drug specifically binds to and inhibits the M3 acetylcholine receptors in bronchial smooth muscle, leading to airway dilation [1]

Core Viewpoint - The company Kyushu Tong (600998.SH) announced that its subsidiary Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd. received approval from the National Medical Products Administration for the marketing application of Glycopyrrolate, a quaternary ammonium anticholinergic drug [1] Group 1: Product Information - Glycopyrrolate selectively acts on the gastrointestinal tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] - The drug specifically binds to and inhibits the M3 acetylcholine receptors in bronchial smooth muscle, leading to airway dilation [1] - Glycopyrrolate is indicated for the treatment of gastric and duodenal ulcers, chronic gastritis, and for maintenance bronchial dilation therapy in adults with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema [1]

Core Viewpoint - The approval of the listing application for Glycopyrrolate by the National Medical Products Administration marks a significant milestone for the company, enhancing its product portfolio in the pharmaceutical market [1] Group 1: Product Approval - The company's subsidiary, Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the approval notice for the listing application of Glycopyrrolate on October 16, 2025 [1] - Glycopyrrolate is a quaternary ammonium anticholinergic drug that selectively acts on the gastrointestinal tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] - The drug can specifically bind to and inhibit the M3 acetylcholine receptors in bronchial smooth muscle, leading to airway dilation [1] Group 2: Product Forms - Glycopyrrolate is available in various formulations, including injection, inhalation powder, inhalation solution, oral solution, tablets, and a combination inhalation aerosol with Formoterol [1] - Some formulations, such as Glycopyrrolate injection and Glycopyrrolate/Formoterol inhalation aerosol, have been included in the medical insurance directory [1] Group 3: Sales Performance - In 2024, the hospital sales of Glycopyrrolate injection reached 53.5772 million yuan, representing a year-on-year growth of 38.29% [1] - In the first half of 2025, the hospital sales of Glycopyrrolate injection amounted to 37.407 million yuan, showing a significant year-on-year increase of 79.21% [1]

Core Viewpoint - The approval of the drug "Gelong Bromide" by the National Medical Products Administration marks a significant milestone for the company, indicating potential growth in the pharmaceutical market [1] Company Summary - The company, Jiuzhoutong, announced that its subsidiary, Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the approval for the listing application of Gelong Bromide on October 16, 2025 [1] - Gelong Bromide is a quaternary ammonium anticholinergic drug that selectively acts on the digestive tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] Product Summary - Gelong Bromide can be used for treating gastric and duodenal ulcers, chronic gastritis, and as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, including chronic bronchitis and emphysema [1] - The drug works by specifically binding to and inhibiting the M3 acetylcholine receptors distributed in bronchial smooth muscle, leading to airway dilation [1]

Core Viewpoint - The approval of the drug "Gelong Bromide" by the National Medical Products Administration marks a significant milestone for the company, enhancing its product portfolio in the pharmaceutical sector [1] Company Summary - The company, through its subsidiary Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the approval for the marketing application of Gelong Bromide on October 16, 2025 [1] - Gelong Bromide is a quaternary ammonium anticholinergic drug that selectively acts on the gastrointestinal tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] Product Details - Gelong Bromide can be used for treating gastric and duodenal ulcers, chronic gastritis, and as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, including chronic bronchitis and emphysema [1] - The drug specifically binds to and inhibits the M3 acetylcholine receptors in bronchial smooth muscle, leading to airway dilation [1]

Core Viewpoint - The approval of the listing application for Glycopyrrolate by the National Medical Products Administration is expected to positively impact the future development of the company's pharmaceutical industrial business and enhance its competitiveness in the active pharmaceutical ingredient market [1] Group 1: Company Developments - The company's subsidiary, Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the approval notice for the listing application of Glycopyrrolate on October 16, 2025 [1] - Glycopyrrolate is a quaternary ammonium anticholinergic drug used for treating gastric and duodenal ulcers, chronic gastritis, and for maintaining bronchial dilation in adult patients with chronic obstructive pulmonary disease [1] - The approval will enrich the company's product line and strengthen its market position in the active pharmaceutical ingredient sector [1]